Intelligent Bio Solutions Inc. (NASDAQ: INBS) is poised to present its innovative pharmacokinetic (PK) study at the ADLM 2025 Clinical Lab Expo in Chicago, showcasing the effectiveness of its Intelligent Fingerprinting Drug Screening System. The study reveals that fingerprint sweat can accurately mirror codeine levels, matching those detected in blood and saliva, thereby affirming the system's potential as a swift, non-invasive, and respectful drug screening solution across various sectors.
Daniel Brown, Head of Clinical Affairs at INBS, is scheduled to share these findings in the Poster Hall sessions. The company's technology, which analyzes fingerprint sweat, presents a hygienic and economical alternative to conventional drug testing methods. Capable of delivering results in less than ten minutes with a sample collection time of just seconds, this system is especially beneficial for industries where safety is paramount. Currently, INBS's innovative solution is being utilized by over 450 clients in 24 countries, spanning industries such as construction, manufacturing, transportation, and drug rehabilitation centers.
The upcoming presentation at the ADLM 2025 Clinical Lab Expo represents a pivotal achievement for INBS, as it seeks to broaden the scope of its fingerprint sweat analysis technology. Beyond validating the system's precision, the study's outcomes pave the way for its application in areas extending past drug screening. For further information on the study and INBS's pioneering technologies, visit https://ibn.fm/suGlJ.
